Literature DB >> 30157404

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Patrick M Forde, Jamie E Chaft, Drew M Pardoll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30157404     DOI： 10.1056/NEJMc1808251

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  42 in total

1.  The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Authors:  Karthik Suresh; Jarushka Naidoo; Qiong Zhong; Ye Xiong; Jennifer Mammen; Marcia Villegas de Flores; Laura Cappelli; Aanika Balaji; Tsvi Palmer; Patrick M Forde; Valsamo Anagnostou; David S Ettinger; Kristen A Marrone; Ronan J Kelly; Christine L Hann; Benjamin Levy; Josephine L Feliciano; Cheng-Ting Lin; David Feller-Kopman; Andrew D Lerner; Hans Lee; Majid Shafiq; Lonny Yarmus; Evan J Lipson; Mark Soloski; Julie R Brahmer; Sonye K Danoff; Franco D'Alessio
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

Review 2.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

Review 3.  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

Authors:  Gavin P Dunn; Timothy F Cloughesy; Marcela V Maus; Robert M Prins; David A Reardon; Adam M Sonabend
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

4.  Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.

Authors:  Shira Peleg Hasson; Benjamin Salwen; Ayelet Sivan; Sivan Shamai; Ravit Geva; Ofer Merimsky; Ari Raphael; Haim Shmilovich; Yonatan Moshkovits; Livia Kapusta; Zach Rozenbaum; Ido Wolf; Michal Laufer-Perl
Journal:  Clin Res Cardiol       Date:  2020-04-15       Impact factor: 5.460

Review 5.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

Review 6.  Combination immunotherapy strategies for glioblastoma.

Authors:  Hok Yee Chan; John Choi; Christina Jackson; Michael Lim
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

7.  Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review.

Authors:  K C Wilson; M P Flood; D Oh; N Calvin; M Michael; R G Ramsay; A G Heriot
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

Review 8.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 9.  Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.

Authors:  Hui Yi Chew; Riccardo Dolcetti; Fiona Simpson
Journal:  Br J Clin Pharmacol       Date:  2020-06-18       Impact factor: 4.335

10.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Authors:  Lorenzo F Fanchi; Krijn K Dijkstra; José G Van den Berg; Emile E Voest; John B Haanen; Myriam Chalabi; Arend G Aalbers; Karolina Sikorska; Marta Lopez-Yurda; Cecile Grootscholten; Geerard L Beets; Petur Snaebjornsson; Monique Maas; Marjolijn Mertz; Vivien Veninga; Gergana Bounova; Annegien Broeks; Regina G Beets-Tan; Thomas R de Wijkerslooth; Anja U van Lent; Hendrik A Marsman; Elvira Nuijten; Niels F Kok; Maria Kuiper; Wieke H Verbeek; Marleen Kok; Monique E Van Leerdam; Ton N Schumacher
Journal:  Nat Med       Date:  2020-04-06       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.